Key result
Single IV PIK7 suppresses ischemia/reperfusion vascular hyperpermeability in rats for up to 90 minutes.
Why the study?
MLCK-dependent endothelial hyperpermeability caused by reactive oxygen species and inflammatory mediators during reperfusion is considered a preventable cause of myocardial ischemia-reperfusion injury.
Does a single intravenous injection of PIK7 reduce vascular hyperpermeability in a rat model of myocardial ischemia-reperfusion injury?
Does a single intravenous injection of PIK7 reduce vascular hyperpermeability in a rat model of myocardial ischemia-reperfusion injury?
Answers are grounded in this paper and cite their sources.
The MLCK inhibitor PIK7 transiently suppresses vascular hyperpermeability in myocardial ischemia-reperfusion injury, and co-administration with SNP improves blood flow in the no-reflow zone.
Myocardial ischemia-reperfusion injury increases myocardial microvascular permeability, leading to enhanced microvascular filtration and interstitial fluid accumulation that is associated with greater microvascular obstruction and inadequate myocardial perfusion. A burst of reactive oxygen species and inflammatory mediators during reperfusion causes myosin light chain kinase (MLCK)-dependent endothelial hyperpermeability, which is considered a preventable cause of reperfusion injury. In the present study, a single intravenous injection of MLCK peptide inhibitor PIK7 (2.5 mg/kg or 40 mg/kg) was found to suppress the vascular hyperpermeability caused by ischemia/reperfusion injury in an in vivo rat model. The antiedemic effect of PIK7 is transient and ceases within 90 min of reperfusion. The early no-reflow detected for the first time after 30 min ischemia in this model of myocardial infarction reduces the area accessible for PIK7. Electron microscopy has shown membrane-bound blebs of endotheliocytes, which partially or completely obturate the capillary lumen, and few capillaries with signs of intercellular gap formation in samples obtained from the center of the early no-reflow zone in control and PIK7-injected rats. Co-injection of PIK7 with NO donor sodium nitroprusside (SNP) increases blood flow in the zone of early no-reflow, while reducing the increased vascular permeability caused by SNP.
No takes yet. Share an insight, caveat, or question.
Сонин et al. (2025) studied Myocardial ischemia-reperfusion injury. MLCK peptide inhibitor PIK7 vs. Control was evaluated on Vascular hyperpermeability. A single intravenous injection of PIK7 (2.5 or 40 mg/kg) suppressed vascular hyperpermeability caused by ischemia/reperfusion injury in a rat model, with the effect ceasing within 90 minutes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: